Institutional investors purchased a net $459.8 thousand shares of MYGN during the quarter ended December 2017 and now own 108.14% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
THE VANGUARD GROUP, INC. Bought 896.1 Thousand shares of Myriad Genetics Inc